Lyme Disease Vaccine Trial Results for Children Released
A four-dose vaccine study has shown safe and tolerable results for children between the ages of 5 and 17.
Updated on Oct. 12, 2026 in Children’s Health
Live Poll
If approved, would you vaccinate your children against Lyme disease?
A phase 3 clinical trial involving 3,547 participants has found that a new four-dose Lyme disease vaccine is safe and tolerable for children. The vaccine works by neutralizing Borrelia burgdorferi bacteria inside a tick during feeding.
Why it matters
The vaccine targets the OspA protein on the surface of Lyme-causing bacteria to prevent infection in younger populations. This development marks a potential return to immunization options after the withdrawal of previous Lyme vaccines.
The study utilized 57 sites across the United States to monitor 3,547 participants. Researchers recorded that 1.5 percent of adverse events within the vaccine group were identified as vaccine-related.
The players
FDA
The Food and Drug Administration is the federal agency responsible for regulating vaccines and determining if this product will be licensed.
The details
The LB6V vaccine delivers protection by targeting six distinct serotypes of the OspA protein. Participants received injections at baseline, 2 months, 6 months, and 18 months, with researchers noting a 0.8 percent withdrawal rate due to adverse events in the 5-11 age group.
Timeline
1998: The LYMErix vaccine received its initial approval.
2002: LYMErix was voluntarily withdrawn from the market.
December 2022: Clinical trial participant enrollment began.
July 2025: Clinical trial participant enrollment concluded.
Health Landscape
This development follows the historical precedent set by the 1998 LYMErix vaccine, which was later removed from the market. The trial signals a major effort to bridge the long-standing gap in preventative options for tick-borne diseases in children.
Families currently have no pediatric Lyme vaccine options, so this trial success brings the prospect of future immunization closer to reality. Parents should continue to rely on existing tick-prevention protocols until official licensing and distribution guidelines are established.
The takeaway
The successful trial of the LB6V vaccine indicates a promising path toward re-establishing Lyme disease prevention for children. Future regulatory reviews will determine when and if this series becomes available for pediatric clinical use.
Further reading
Find more information on preventative care and immunity in our Children’s Health section.
Source note: This article includes information reported by Medscape.
Live Poll
If approved, would you vaccinate your children against Lyme disease?
